Gilead Continues Oncology Spree with US$2.2 B Arcus Deal

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 6 (Table of Contents)

Published: 3 Jun-2020

DOI: 10.3833/pdr.v2020.i6.2541     ISSN: 1756-7874

Section: Research & Development



In a bid to build on its growing immuno-oncology presence, Gilead Sciences has formed a 10-year partnership with Arcus Biosciences to jointly develop and commercialise all current and future therapeutic product candidates in Arcus’s pipeline in exchange for US$375 M upfront...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details